14-3-8　ⓔ文献

  1. Doutrelepont JM, Adler M, et al: Hepatitis C infection and membranoproliferative glomerulonephritis. Lancet, 1993; 341: 317.

  2. Bishof NA, Welch TR, et al: DP polymorphism in HLA–A1, –B8, –DR3 extended haplotypes associated with membranoproliferative glomerulonephritis and systemic lupus erythematosus. Pediatr Nephrol, 1993; 7: 243–246.

  3. Sun IO, Hong YA, et al: Type III membranoproliferative glomerulonephritis in a patient with primary Sjögren’s syndrome. Clin Nephrol, 2013; 79: 171–174.

  4. Sethi S, Zand L, et al: Membranoproliferative glomerulonephritis secondary to monoclonal gammopathy. Clin J Am Soc Nephrol, 2010; 5: 770–782.

  5. Sethi S, Fervenza FC: Membranoproliferative glomerulonephritis a new look at an old entity. N Engl J Med, 2012; 366: 1119–1131.

  6. Koscielska–Kasprzak K, Bartoszek D, et al: The complement cascade and renal disease. Arch Immunol Ther Exp (Warsz), 2014; 62: 47–57.

  7. Nakagawa N, Hasebe N, et al: Clinical features and pathogenesis of membranoproliferative glomerulonephritis: a nationwide analysis of the Japan renal biopsy registry from 2007 to 2015. Clin Exp Nephrol, 2018; 22: 797–807.

  8. Jones DB: Glomerulonephritis. Am J Pathol, 1953; 29: 33–51.

  9. Zhou X, Silva F: Membranoproliferative Glomerulonephritis. Heptinstall’s Pathology of the Kidney, 7th ed (Jennette J, Olson J, et al eds), Wolters Kluwer, 2014; 301–340.

  10. Appel GB, Cook HT, et al: Membranoproliferative glomerulonephritis type II (dense deposit disease): an update. J Am Soc Nephrol, 2005; 16: 1392–1403.

  11. Nakano M, Karasawa K, et al: Characteristics of membranoproliferative glomerulonephritis based on a new classification at a single center. Clin Exp Nephrol, 2019; 23: 852–858.

  12. Medjeral-Thomas NR, O’Shaughnessy MM, et al: C3 glomerulopathy: clinicopathologic features and predictors of outcome. Clin J Am Soc Nephrol, 2014; 9: 46–53.

  13. Bomback AS, Santoriello D, et al: C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy. Kidney Int, 2018; 93: 977–985.

  14. Bomback AS, Appel GB: Pathogenesis of the C3 glomerulopathies and reclassification of MPGN. Nat Rev Nephrol, 2012; 8: 634–642.

  15. Cameron JS, Turner DR, et al: Idiopathic mesangiocapillary glomerulonephritis. Comparison of types I and II in children and adults and long–term prognosis. Am J Med, 1983; 74: 175–192.

  16. Faedda R, Satta A, et al: Immunosuppressive treatment of membranoproliferative glomerulonephritis. Nephron, 1994; 67: 59–65.

  17. Pol S, Parlati L: Hepatitis C virus and the kidney. Nat Rev Nephrol, 2019; 15: 73-86.

  18. Goodship TH, Cook HT, et al: Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. Kidney Int, 2017; 91: 539–551.